FidaxoMicin
- CAS No.
- 873857-62-6
- Chemical Name:
- FidaxoMicin
- Synonyms
- Fidaxomicin Crystalline;Dificid;OPT-80;CS-741;PAR-101;fedamycin;FidaxoMicin;Fidaxomycin;FidaxoMicinr;Not for drug
- CBNumber:
- CB02582922
- Molecular Formula:
- C52H74Cl2O18
- Molecular Weight:
- 1058.04
- MOL File:
- 873857-62-6.mol
- MSDS File:
- SDS
- Modify Date:
- 2023/9/7 18:57:57
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335 | |||||||||
| Precautionary statements | P280-P305+P351+P338-P321 | |||||||||
| HS Code | 2941900000 | |||||||||
| NFPA 704 |
|
FidaxoMicin price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML1750 | Fidaxomicin ≥98% (HPLC) | 873857-62-6 | 1MG | ₹34932.28 | 2022-06-14 | Buy |
| TCI Chemicals (India) | F1216 | Fidaxomicin | 873857-62-6 | 25MG | ₹6600 | 2022-05-26 | Buy |
| TCI Chemicals (India) | F1216 | Fidaxomicin | 873857-62-6 | 100MG | ₹14800 | 2022-05-26 | Buy |
FidaxoMicin Chemical Properties,Uses,Production
Description
Fidaxomicin (OPT-80) was approved by the U.S. FDA in May 2011 for
the treatment of Clostridium difficile-associated diarrhea (CDAD), joining
metronidazole and vancomycin as drugs recommended for treatment of
C. difficile infections (CDI). Fidaxomicin, also known as
lipiarmycin and tiacumicin, is an 18-membered macrolide natural
product that was first reported in mid-1970s and is produced by
fermentation. Fidaxomicin and its primary metabolite OP-1118,
which results from hydrolysis of the isobutyryl ester, are narrowspectrum
antibacterial agents with activity against gram-positive aerobic
and anaerobic organisms, but not against gram-negative organisms.
Fidaxomicin and OP-1118 exert their antibacterial activity by inhibiting
bacterial RNA polymerase, thereby inhibiting bacterial protein
synthesis.
The MIC90 (minimum inhibitory concentration to kill 90% of
bacteria) for fidaxomicin against C.difficile is 0.125–0.25 μg/mL; OP-
1118 is 4- to 16-fold less potent than the parent compound.
Fidaxomicin has been reported to spare native intestinal flora such as
Bacteroides spp. and as such, may prevent selection of drug-resistant
bacteria. Fidaxomicin is bactericidal to C. difficile and has a low
propensity for resistance development with no cross-resistance to
existing antibiotics. Fidaxomicin shows minimal systemic absorption following oral administration in preclinical studies and humans.
Uses
Fidaxomicin is a recently marketed antibiotic with a confusing history dating back to its original isolation in 1975. Fidaxomicin is the major analogue of a family of macrocyclic lactones, isolated independently by three different groups from cultures belonging to three different genera (Actinoplanes, Dactylosporangium and Micromonospora) known as lipiarmycin A3, tiacumicin B and clostomicin B1, respectively. Fidaxomicin is a narrow spectrum antibiotic with excellent activity against Gram positive bacteria, notably Clostridium difficile. Fidaxomicin acts in the gastrointestinal tract without undue disruption to gut microbial flora.
Definition
ChEBI: An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.
Pharmaceutical Applications
Formerly known as difimicin. An 18-membered macrocyclic compound related to the tiacumicin group of antibiotics rather than conventional macrolides. It is active against staphylococci (MIC 0.5–2 mg/L) and most anaerobic Grampositive bacilli and cocci, but Gram-negative bacilli, including Gram-negative anaerobes, are resistant. It is very poorly absorbed when given orally and most interest surrounds its activity against C. difficile (MIC 0.12–0.25 mg/L). Such data as are presently available from clinical trials suggest that it is as safe and effective in the treatment of C. difficile-associated diarrhea as vancomycin.
FidaxoMicin Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Concord Biotech Limited | +91-2714398200 +91-2714398200 | Gujarat, India | 22 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Vista Inc. | 09177778907 | Maharashtra, India | 7 | 58 | Inquiry |
| Angel Bio Pharma | 08069013898Ext 347 | Ahmedabad, India | 50 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
| Fuxin Pharmaceutical | +86-021-021-50872116 +8613122107989 | China | 10297 | 58 | Inquiry |
| Hangzhou ICH Biofarm Co., Ltd | +86-0571-28186870; +undefined8613073685410 | China | 985 | 58 | Inquiry |